Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) Q1 2024 Earnings Call Transcript
Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) Q1 2024 Earnings Call Transcript May 14, 2024Atea Pharmaceuticals, Inc. misses on earnings expectations.
Atea Pharmaceuticals Inc. (AVIR)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | EcoR1 Capital Oleg Nodelman | 6,145,861 | $24,829,278 | -13% | 0.62% |
| 2. | Tang Capital Management Kevin C. Tang | 4,076,741 | $16,470,034 | 1.71% | |
| 3. | Two Sigma Advisors John Overdeck And David Siegel | 577,400 | $2,332,696 | +81% | 0% |
| 4. | Newtyn Management Noah Levy And Eugene Dozortsev | 400,000 | $1,616,000 | -22% | 0.32% |
| 5. | Millennium Management Israel Englander | 212,763 | $859,563 | +1264% | 0% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $8.57 | 12,000 | Director | 23,295 | 2021-12-20 | Filing | |
| $24.00 | 7,292 | Large Shareholder | 289,695 | 2020-11-03 | Filing | |
| $24.00 | 242,708 | Large Shareholder | 1,654,724 | 2020-11-03 | Filing | |
| $24.00 | 250,000 | Director | 5,615,659 | 2020-11-03 | Filing | |
| $24.00 | 41,666 | Director | 820,019 | 2020-11-03 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $3.49 | 17,544 | 65,606 | 2024-06-20 | Filing | ||
| $4.00 | 1,006 | 5,923,994 | 2024-06-05 | Filing | ||
| $3.84 | 15,843 | 670,208 | 2024-02-01 | Filing | ||
| $3.85 | 56,910 | 116,557 | 2024-02-01 | Filing | ||
| $3.84 | 15,870 | 25,664 | 2024-02-01 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 9,443,887 | $28,803,855 | 0% | |
| 2. | 5,462,079 | $16,659,341 | 12.61% | |
| 3. | 5,350,659 | $16,319,511 | 0% | |
| 4. | 4,599,710 | $14,029,115 | 0% | |
| 5. | 2,485,638 | $7,581,196 | 0.72% |
News See All
Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) Q4 2023 Earnings Call Transcript
Operator: Good afternoon, everyone, and welcome to the Atea Pharmaceuticals Fourth Quarter 2023 Financial Results and Business Update Conference Call.
Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) Q3 2023 Earnings Call Transcript
Operator: Good afternoon, ladies and gentlemen. Welcome to the Atea Pharmaceuticals Third Quarter 2023 Financial Results and Business Update Conference Call. [Operator Instructions].
Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) Q2 2023 Earnings Call Transcript
Operator: Good afternoon, ladies and gentlemen. Welcome to the Atea Pharmaceuticals Second Quarter 2023 Financial Results and Business Update Conference Call.
Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) Q1 2023 Earnings Call Transcript
Operator: Good afternoon, ladies and gentlemen. Welcome to the Atea Pharmaceuticals’ First Quarter 2023 Financial Results and Business Update Conference Call.
Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) Q4 2022 Earnings Call Transcript
Operator: Good afternoon, ladies and gentlemen. Welcome to the Atea Pharmaceuticals' Fourth Quarter and Full Year 2022 Financial Results and Business Update Conference Call.
10 New Stock Picks of Billionaire Rob Citrone
Rob Citrone is an American hedge fund manager who in 1999 co-founded Discovery Capital Management, a hedge fund that focuses its investments on emerging markets and has a Q3 13F portfolio worth $1.3 billion...
5 Latest Stock Picks of Chinese Billionaire Chen Tianqiao's Shanda Asset Management
In this piece, we will take a look at the 5 latest stock picks of Chinese billionaire Chen Tianqiao's Shanda Asset Management. If you want to learn more about Mr.
Hedge Funds Are Piling Into Atea Pharmaceuticals, Inc. (AVIR)
The financial regulations require hedge funds and wealthy investors that exceeded the $100 million holdings threshold to file a report that shows their positions at the end of every quarter.
15 Pharmaceutical Stocks to Buy According to Peter Kolchinsky's RA Capital
In this piece, we will take a look at the top 15 pharmaceutical stocks to buy according to Peter Kolchinsky's RA Capital.
Billionaire Hedge Funds
